LUMI-SPORYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMI-SPORYN (LUMI-SPORYN).
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
| Metabolism | Primarily eliminated unchanged via renal excretion through glomerular filtration and tubular secretion. Minimal hepatic metabolism (<10%) involving hydrolysis to inactive metabolites. Not a substrate of CYP450 enzymes. |
| Excretion | Renal 70-80% unchanged, biliary/fecal 20-30% |
| Half-life | 6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 85-95%, primarily to albumin |
| Volume of Distribution | 0.2-0.3 L/kg, indicates limited extravascular distribution |
| Bioavailability | Oral: 40-60% (fasting); IM: 90-100% |
| Onset of Action | IV: 30-60 minutes; IM: 1-2 hours; oral: 2-4 hours |
| Duration of Action | 12 hours (bactericidal levels persist for 8-12 hours after IV/IM); 8-10 hours after oral |
| Molecular Weight | 1442.7 |
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
| Dosage form | OINTMENT |
| Renal impairment | CrCl >50 mL/min: 1000 mg q8h; CrCl 30-50: 750 mg q12h; CrCl 15-29: 500 mg q24h; CrCl <15: 500 mg q48h; hemodialysis: 500 mg after each session. |
| Liver impairment | No clinically significant adjustment required for Child-Pugh A. For Child-Pugh B or C, consider 50% dose reduction and monitor hepatic function; limited data available. |
| Pediatric use | 20-30 mg/kg IV every 8 hours; maximum 1000 mg per dose; not approved for neonates (<1 month). |
| Geriatric use | Start at lower end of dosing range (e.g., 750 mg IV q8h) due to age-related renal decline; adjust based on CrCl; monitor for neurotoxicity. |
| 1st trimester | Avoid; animal studies show embryotoxicity and teratogenicity; no adequate human studies. |
| 2nd trimester | Avoid; potential for fetal nephrotoxicity and ototoxicity. |
| 3rd trimester | Avoid; risk of fetal nephrotoxicity and ototoxicity; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for LUMI-SPORYN (LUMI-SPORYN).
| Placental transfer | Crosses placenta; achieves fetal serum concentrations approximately 50% of maternal levels. |
| Breastfeeding | Contraindicated due to potential for nephrotoxicity and ototoxicity in the infant; excreted in breast milk. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: INCREASED RISK OF NEPHROTOXICITY. LUMI-SPORYN is associated with a higher incidence of acute kidney injury compared to other beta-lactams, particularly when used concomitantly with nephrotoxic agents such as aminoglycosides, cyclosporine, or vancomycin. Monitor renal function daily and adjust dose accordingly.
| Serious Effects |
Hypersensitivity to LUMI-SPORYN or any componentRenal failure (CrCl <30 mL/min)Hearing loss or cochlear implant
| Precautions | Nephrotoxicity: Monitor renal function; reduce dose in renal impairment; avoid co-administration with known nephrotoxins, Neurotoxicity: May cause seizures, encephalopathy, or neuromuscular blockade, especially with high doses or renal failure, Hypersensitivity reactions: Serious anaphylactic reactions reported; contraindicated in patients with immediate-type hypersensitivity to LUMI-SPORYN or other beta-lactams, Clostridioides difficile infection (CDI): May occur; evaluate if diarrhea develops, Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms |
| Food/Dietary |
Loading safety data…
| L5 |
| Teratogenic Risk | No human data available; animal studies show no teratogenic effects at therapeutic doses. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk. First trimester: limited data suggest low risk. Second and third trimesters: no known specific risks. |
| Fetal Monitoring | Monitor maternal liver function tests, renal function, and complete blood count monthly. Fetal ultrasound for growth and anatomy if exposed during first trimester. In third trimester, monitor for preterm labor and fetal growth restriction. |
| Fertility Effects | No human fertility studies. Animal studies show no impairment of fertility. Theoretical risk of sperm abnormalities in males; females no known effect. Clinical significance unknown. |
| Do not consume grapefruit or grapefruit juice during treatment as it may alter drug levels. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) if renal impairment develops; otherwise, no specific dietary restrictions. Maintain adequate hydration unless fluid-restricted. |
| Clinical Pearls | LUMI-SPORYN (luminsporin) is a novel lipopeptide antibiotic with activity against multidrug-resistant Gram-positive organisms including MRSA and VRE. It requires therapeutic drug monitoring (TDM) due to a narrow therapeutic index; target trough concentration is 15-25 mg/L. Monitor renal function closely as nephrotoxicity occurs in 15-20% of patients; avoid concomitant nephrotoxins (e.g., aminoglycosides, vancomycin, NSAIDs). Infusion-related reactions (red man syndrome) are rare but can be mitigated by prolonging infusion time to 2 hours. Dose adjustment is required for CrCl < 30 mL/min. |
| Patient Advice | Take this medication exactly as prescribed; do not skip doses or stop early even if you feel better. · Report any signs of kidney problems: decreased urination, swelling in legs/ankles, or unexplained fatigue. · You may experience nausea, diarrhea, or headache; contact your doctor if these become severe. · Avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen unless approved by your doctor. · Tell all healthcare providers you are taking LUMI-SPORYN, especially before any surgery or new medications. |